In a significant achievement for GT Biopharma, Inc., the FDA has granted clearance for the company's Investigational New Drug (IND) application for GTB-3650, a novel NK cell engager aimed at treating CD33+ leukemia. This regulatory milestone allows the clinical-stage immuno-oncology company to
The healthcare system's history of unethical practices and ongoing issues has fostered a deep mistrust among minority communities. This mistrust affects everything from routine healthcare appointments to participation in clinical trials. Despite significant efforts to increase diversity,
Recent clinical advancements by PolTREG, a pioneering Polish biotechnology company, have cast a hopeful light on the treatment of type-1 diabetes (T1D). The company's breakthrough Treg therapy, PTG-007, has shown great promise in fundamentally altering the management of this autoimmune
Huntington’s disease, a genetic disorder that leads to the gradual death of nerve cells in the brain, has long challenged the medical and scientific communities. Traditional treatments have provided only limited symptom relief, pushing the quest for innovative therapies that can alter the disease’s
Artificial Intelligence (AI) is poised to transform drug discovery, ushering in an era of unprecedented innovation in the pharmaceutical industry. The promise of developing numerous high-quality drug candidates quickly and cost-effectively is becoming a reality. However, this revolution also brings
Auxilius, a company specializing in Clinical Trial Financial Management (CTFM) software for the biopharma industry, has recently raised $10 million in financing led by SignalFire. With an astounding 800% year-over-year growth in annual recurring revenue (ARR) for 2023, this upsurge underscores the